Depomed, Inc. (NASDAQ:DEPO) announced today a product license agreement under which Solvay Pharmaceuticals will have exclusive rights for DM-1796 (formerly Gabapentin GR®) for the treatment of pain in the United States, Canada, Mexico and Puerto ...
- Recent posts
- Can I get a second opinion for my pain management? | Acute Pain...
- Depomed, Inc. Announces Exclusive North American License Agreement ... - PR Inside
- Mindfulness Meditation » Living Mindfully: What the Yoga Teacher ...
- Is Religious Practice Better Than Medicine? - WJZ
- Solvay Pharmaceuticals, Inc. Announces Exclusive North American - MSN MoneyCentral
- 'Tis the Season - Modesto Bee
- Pain management center to cut hours in half - EagleTribune.com ...
- A multifactorial strategy of pain management is associated with ...
- United, Villarreal ground out another stalemate - Sabah Daily Express
- Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the ... - Yahoo Finance
- Carrying on with self-management strategies doesn’t make a ...
- Your mail: Handle with care - Alexandria Daily Town Talk
- Maumee workshop to focus on care for elderly - Toledo Blade
- The Role of Stress in Chronic Pain Management | addiction-free.com
- Fogster | Fibromyalgia/Stress/Pain BLR MFT - (Pleasanton)
- US automakers beg for $25 billion lifeline - International Herald Tribune
- Advances in Pain Management: Emerging Strategies and Clinical ... - Medscape News
- Pain Management..
- The ACCORD Program: Working Together for the Management of Chronic ... - CNW Group
- Transdel Pharmaceuticals to Present at Rodman & Renshaw 10th Annual ... - MSN MoneyCentral